Overview
This actively managed equity fund invests in companies from across the globe that offer a high dividend yield
The fund focuses on quality factors to exclude low quality stocks, including the company’s ability to pay stable or growing dividends
The portfolio offers high diversification with low single stock weightings and diversified country and sector allocations
UBS High Dividend Funds have typical equity risk characteristics and are designed for risk tolerant investors who are willing to bear the risk and volatility of equity investments
Local currency risks are largely hedged versus USD.
The strategy is based on a quantitative model.
This fund promotes environmental, social and corporate governance characteristics. The research and portfolio construction processes incorporate ESG risk integration and screening and comply with UBS SA国际传谋 Sustainability exclusion policy. For more information on Sustainability at UBS, please refer to www.ubs.com/am-si-commitment.
The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
Benefits
Easy access to stocks from across the globe that offer high dividend yields.
The focus on high quality stocks aims to exclude companies that do not pay sustainable dividends.
Investors can profit from a portfolio that seeks optimal diversification - low single stock weights and broad country and sector allocations.
Investors can largely avoid the impact from fluctuations of the local investment currencies versus USD
Risks
Features
| Product category |
Equity Global |
| Product domicile |
Luxembourg
|
| Portfolio management |
UBS SA国际传谋 Switzerland AG, Zurich
|
| Fund management |
UBS SA国际传谋 (Europe) S.A., Luxembourg
|
| Custodian bank |
UBS Europe SE, Luxembourg Branch
|
| Representative for products established under foreign law |
UBS Fund Management (Switzerland) AG
|
| Regulation |
UCITS
|
| Legal form |
Unlimited
|
| Day of inception |
January 17, 2013
|
| Currency of account |
USD
|
| Close of financial year |
May 31
|
| SFDR Classification |
Art.8
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
0.67% p.a.
|
| Flat fee |
0.64% p.a.
|
| Management fee |
0.51% p.a.
|
| Total expense ratio (TER) |
0.67% p.a.
|
| Swing pricing |
yes
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
MSCI All Country World (net div. reinv.) (hedged USD)
|
| Cut-Off Time |
15:00h(CET)
|
| Securities no. |
18994882
|
| ISIN |
LU0804734431
|
| Bloomberg Ticker |
UHUSIA1 LX
|
| Telekurs Id |
n.a.
|
Performance and Prices
Percentage growth
as of April 23, 2026| USD(%) | CHF(%) | EUR(%) | |
| YTD | 11.43 | 10.22 | 11.74 |
| 1M | |||
| 3M | |||
| 6M | |||
| 1Y | |||
| 2Y | 15.32 | 0.81 | 1.67 |
| 3Y | |||
| 5Y | 69.83 | 45.15 | 74.74 |
| ø p.a.5Y | 11.17 | 7.74 | 11.81 |
Current data
| Net asset value | 23.04.2026 | USD 348.15 |
| High - last 12 months | 20.04.2026 | USD 349.17 |
| Low - last 12 months | 24.04.2025 | USD 265.03 |
| Assets of the unit class in mn | 23.04.2026 | USD 11.51 |
| Total product assets in mn | 23.04.2026 | USD 1,119.35 |
| Indicative current dividend yield | 31.03.2026 | 3.00% |
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 31.03.2026 | 9.80% | 13.05% |
| Sharpe Ratio | 31.03.2026 | 0.99 | 0.57 |
| Risk Free Rate | 31.03.2026 | 4.55% | 3.51% |
Structures
By the 10 largest equity positions (in %, as of March 31, 2026)
|
|
|
| Best Buy Co Inc | 1.09 |
| Engie SA | 1.09 |
| Pfizer Inc | 1.08 |
| Bristol-Myers Squibb Co | 1.08 |
| Fastenal Co | 1.07 |
| AbbVie Inc | 1.06 |
| Sanofi SA | 1.06 |
| LyondellBasell Industries NV | 1.06 |
| Equinor ASA | 1.06 |
| Exelon Corp | 1.05 |
Fees
Distributions
Sales Authorisations
Literature
|
Document type
|
Document Language
|
|||
| Prospectus |
|
|
||
| Key Information Document |
|
|
|
|
| Past performance |
|
|
|
|
| Previous performance scenario |
|
|
|
|
| Statutes / Management regulations |
|
|
||
| ESG Disclosure |
|
|||
| SFDR Pre-Contractual Annex |
|
|
Document type
|
Document Language
|
||
| Annual report |
|
|
|
| SFDR Periodic Report Annex |
|
||
| Semi-annual report |
|
|
|